Kazuhiro Ikegame

Kazuhiro Ikegame

Auto-generated profile, based on publicly available information

Kazuhiro Ikegame

Hematopoietic Cell Transplantation Center, Aichi Medical University School of Medicine, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MMMakoto Murata
Makoto Murata
STSeitaro Terakura
Seitaro Terakura
AWAtsushi Wake
Atsushi Wake
KMKotaro Miyao
Kotaro Miyao
KIKazuhiro Ikegame
Kazuhiro Ikegame
TTTakanori Teshima
Takanori Teshima

8 June 2020 in Mycoses
Verified
Journal Article
Open access
PDF file
Yukihiro HamadaYukihiro Hamada
Yukihiro Hamada
TUTakashi Ueda
Takashi Ueda
YMYoshitsugu Miyazaki
Yoshitsugu Miyazaki
KNKazuhiko Nakajima
Kazuhiko Nakajima
KFKeiko Fukunaga
Keiko Fukunaga
YTYoshio Takesue
Yoshio Takesue
Summary: Background: Hepatotoxicity and visual symptoms are common adverse effects (AEs) of voriconazole therapy.Objective: To retrospectively evaluate the effects of treatment modification based on therapeutic drug monitoring on AEs in patients undergoing voriconazole therapy.Methods: The target voriconazole trough concentration (Cmin) was 1‐5 µg/mL. Receiver operating characteristic curves were used to determine Cmin cut‐offs for AEs.Results: A total of 401 patients were included. Among 108 patients with high initial Cmin, voriconazole was discontinued in 32 and the dose was reduced in 71. Among 44 patients with low initial Cmin, voriconazole was discontinued in 4 and the dose was increased in 19. Hepatotoxicity occurred in 6.0% of patients, after a median of 10 days. Visual symptoms were evident in 9.5% of patients after a median of 4 days. Initial Cmin was significantly associated with visual symptoms but not hepatotoxicity, which suggested the effect of treatment modification on hepatotoxicity. However, both hepatotoxicity and visual symptoms were significantly correlated with Cmin at the onset of AEs, and the Cmin cut‐offs were 3.5 μg/mL for hepatotoxicity and 4.2 μg/mL for visual symptoms. Voriconazole was discontinued after the occurrence of AEs in 62.5% of patients with hepatotoxicity but only 26.3% of patients with visual symptoms. With dose adjustment, treatment was completed in 8/9 patients with hepatotoxicity and 27/28 patients with visual symptoms.Conclusions: A significant preventive effect was demonstrated on hepatotoxicity, but not on visual symptoms because of earlier occurrence. With treatment modification after the occurrence of AEs, most patients completed therapy.

13 February 2016 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
KIKazuhiro Ikegame
Kazuhiro Ikegame
KIKohsuke Imai
Kohsuke Imai
MYMotoi Yamashita
Motoi Yamashita
AHAkihiro Hoshino
Akihiro Hoshino
HKHirokazu Kanegane
Hirokazu Kanegane
HOHiroyasu Ogawa
Hiroyasu Ogawa
We herein report the first case of X-linked agammaglobulinemia (XLA) that underwent allogeneic stem cell transplantation using reduced intensity conditioning (RIC). We chronologically observed the reconstitution of humoral immunity in this case. The patient was a 28-year-old Japanese male with XLA who previously had life-threatening infectious episodes and was referred for the possible indication of allogeneic stem cell transplantation. After a thorough discussion within specialists from different backgrounds, we decided to perform allogeneic peripheral stem cell transplantation from his HLA-identical elder brother. Due to the non-malignant nature of XLA, we selected RIC consisting of fludarabine, cyclophosphamide, anti-thymocyte globulin, and 3 Gy of total body irradiation. Neutrophil engraftment was achieved on day 11 with complete donor chimerism. No major complications, except for stage 1 skin graft-versus-host disease, were observed. The patient was discharged on day 75 and has been followed as an outpatient without any infectious episodes for more than 500 days. Regarding immune reconstitution, CD19+ cells, IgA, and IgM, which were undetectable before allogeneic stem cell transplantation (allo-SCT), started to increase in number 10 days after allo-SCT and continued to increase for more than 1 year. Anti-B antibodies appeared as early as day 10. Total IgG levels decreased after the discontinuation of IgG replacement and spontaneously recovered after day 350. However, most anti-viral IgG titers, except EB virus-virus capsid antigen IgG, disappeared after the discontinuation of IgG replacement. A seasonal vaccination to influenza was performed on day 148, with neither anti-influenza type A nor type B being positive after the vaccination. The transient transfer of allergic immunity to orchard grass was observed. Similar Bruton’s tyrosine kinase (BTK) expression levels in monocytes and B-cells were observed between the patient and healthy control. B-cells in the peripheral blood (PB) of the patient on day 279 showed sufficient proliferation after a CD40L and IL-21 or CD40L and CpG stimulation. Effective immunoglobulin production and class switching were also observed after a CD40L and IL-21 or CpG stimulation. Signal joint kappa-deleting recombination excision circles (sjKRECs) became positive 16 days post-SCT, increased to 6300 copies/μg DNA at 42 days, and were maintained at a high level thereafter. The recovery of T-cell receptor excision circles (TRECs) was slow, but became detectable 1 year post-hematopoietic stem cell transplantation (HSCT).

6 February 2017 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
TYT Yamashita
T Yamashita
KIK Ikegame
K Ikegame
HKH Kojima
H Kojima
HTH Tanaka
H Tanaka
KKK Kaida
K Kaida
HOH Ogawa
H Ogawa
Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation


4 February 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
YOYasuhiro Okamoto
Yasuhiro Okamoto
KKKazuko Kudo
Kazuko Kudo
KTKen Tabuchi
Ken Tabuchi
DTDaisuke Tomizawa
Daisuke Tomizawa
TTTakashi Taga
Takashi Taga
HIHiroyuki Ishida
Hiroyuki Ishida
Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19-28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36-57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1-2, 3-4, 5, and 6-7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.